chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Arm was hurting; she lived through the arm pain; trouble sleeping; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 60 year-old female patient received bnt162b2 (BNT162B2), administration date 13Mar2021 (Batch/Lot number: unknown) at the age of 60 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Atrial fibrillation", start date: Dec2020 (ongoing), notes: Verbatim: AFib; "Covid-19", start date: Dec2020 (unspecified if ongoing), notes: Caller reported that she has been taking the blood thinner since Dec2020 when she had Covid-19. The patient took concomitant medications. Past drug history included: Levothyroxin for Thyroid, notes: Dose: Daily; Calcium for Stopped making own calcium, notes: Dose: Everyday; Coq-10, notes: Dose: Everyday, Doctor said it helps with heart medication.  The following information was reported: LIMB DISCOMFORT (non-serious) with onset 13Mar2021, outcome "recovered" (18Mar2021), described as "Arm was hurting"; PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "she lived through the arm pain"; INSOMNIA (non-serious) with onset 2021, outcome "unknown", described as "trouble sleeping".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
In  the spring after her vaccination, patient developed increased nasal congestion and sinus pain.  She was seen in the summer of 2021 by both an Allergist and an ENT for what was thought to be worsening allergies. They all missed that she had Wegener's GPA.  She was treated by multiple providers with antibiotics and allergy medication, but she did not have a sinus infection.   She developed a cough and fatigue in September 2021. She was treated with steroids along with a 2nd course of antibiotics,  and then a 3rd antibiotic without any lab testing.  She died on  October 12, 2021 at hospital after having a bronchoscopy.  She was not diagnosed with Wegener's GPA until after she passed.
Nausea; Fever; Fatigue; Chest pain; Difficulty breathing; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, #lot: Er2613) via an unspecified route of administration administered in Arm Right on 24Mar2021 and second dose (#lot: Er8629) via an unspecified route of administration administered in Arm Right on 14Apr2021 as single dose (at the age of 49-years-old) for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced nausea, fever, fatigue, chest pain and difficulty breathing on an unspecified date. The patient did not report this because he didn't think it was relevant until recent media about myocarditis. He was close 3x to dialing 911 thought was having heart attack. The outcome of all the events was unknown.  Information on Lot/Batch number was available. Additional information has been requested.
Extra dose administered; blister around mouth; blister around nose area/ almost blister looking; very itchy; arm still very red; arm still very sore; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of oral mucosa blister in a 66-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On 06-SEP-2023, the patient received the 3rd dose of Shingrix. On 06-SEP-2023, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Extra dose administered). In SEP-2023, the patient experienced oral mucosa blister (Verbatim: blister around mouth), blister (Verbatim: blister around nose area/ almost blister looking), pruritus (Verbatim: very itchy), erythema of extremities (Verbatim: arm still very red) and pain in arm (Verbatim: arm still very sore).  The outcome of the oral mucosa blister, blister and pruritus were not reported and the outcome of the erythema of extremities and pain in arm were not resolved and the outcome of the extra dose administered was unknown.   It was unknown if the reporter considered the oral mucosa blister, blister, pruritus, erythema of extremities and pain in arm to be related to Shingrix.     It was unknown if the company considered the oral mucosa blister, blister, pruritus, erythema of extremities and pain in arm to be related to Shingrix.   Additional Information: GSK receipt date: 08-SEP-2023 This case was reported the patient via (Shingrix GSK) interactive digital media. The patient received the shot and was very itchy, blister looking around mouth and nose. The patient's arm was still (at the time of reporting), was very sore and red. The patient received the 3rd shot which led to extra dose administered. Follow-up not possible as no contact details provided
About 1 1/2 weeks after first shot I started having dizzy spells but didn't feel like anything I ever felt. It was a little different.  Within a week from that point I started getting disorienting head rushes that made me feel off balance.  I started searching what the feeling I was getting was. I've never had vertigo before but I'm 100% sure that's what is going on.  About 2 weeks after the  second shot not only have the rushes of vertigo gotten way more  extreme,  but I'm also feeling almost under the influence constantly.  My head is in the clouds. I've researched it and it seems the same  thing is happening to many people.  I've read threads where people are explaining exactly what I'm going through.  Some say it goes  away or becomes manageable but others say they've been dealing with it for months.  This is something very new to me and I'm positive that it's vaccine related.  The timing after each  shot was almost spot on with the problem.  I would really like some information on how long I should expect to feel this way.
fever 104 28MAY97 papular rash c/w chicken pos d/t vaccine;
received expired vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received expired vaccine) in a 37-year-old male patient who received mRNA-1273 (COVID 19 Vaccine Moderna) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Dec-2021 at 3:49 AM, the patient received second dose of mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular) .5 milliliter. On 17-Dec-2021 at 3:49 AM,  after starting mRNA-1273 (COVID 19 Vaccine Moderna), the patient experienced EXPIRED PRODUCT ADMINISTERED (received expired vaccine). On 17-Dec-2021 at 3:49 AM, EXPIRED PRODUCT ADMINISTERED (received expired vaccine) had resolved.        For mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication details was provided. No treatment medication details was provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-Dec-2021: Follow up document received included E-mail ID confirmed and document contains Non-significant information.
Patient came in for 2nd covid Pfizer vaccine per mother of child. Mother of child did not present previous vaccine card from past covid injections, per patients chart patient only received 1 dose and was due for 2nd dose, clarified with mother patient needed second dose and mother agreed and completed form to give vaccine, a vaccine card was completed and given to mother with both dates that were in patients chart. 20 minutes after the appointment was completed patients mother went to front desk and gave them an original card that mother had had but did not give to RN at time of visit, patient had no side effects and left facility with no issues
Hospitalized for fever, seizure, pneumonia 9/3/21 Death by cardiac arrest from blood clot on September 16, 2021
shooting nerve pain for three days; random itching and aching; random itching and aching; hot to the touch; headache; swollen lymph nodes; fatigue; red, swollen lump; red, swollen lump; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (red, swollen lump), NEURALGIA (shooting nerve pain for three days), PRURITUS (random itching and aching), PAIN (random itching and aching) and INJECTION SITE WARMTH (hot to the touch) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, the patient experienced VACCINATION SITE MASS (red, swollen lump) and VACCINATION SITE ERYTHEMA (red, swollen lump). On an unknown date, the patient experienced NEURALGIA (shooting nerve pain for three days), PRURITUS (random itching and aching), PAIN (random itching and aching), INJECTION SITE WARMTH (hot to the touch), HEADACHE (headache), LYMPHADENOPATHY (swollen lymph nodes) and FATIGUE (fatigue). At the time of the report, VACCINATION SITE MASS (red, swollen lump), NEURALGIA (shooting nerve pain for three days), PRURITUS (random itching and aching), PAIN (random itching and aching), INJECTION SITE WARMTH (hot to the touch), VACCINATION SITE ERYTHEMA (red, swollen lump), HEADACHE (headache), LYMPHADENOPATHY (swollen lymph nodes) and FATIGUE (fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Treatment medication provided. No concomitant medications provided.
Patient had recent endarterectomy presented to ED with c/o of stating her oxygen has been dropping.  Patient has mild pain on left side,  in ED CT showed severe bilateral multifocal mixed interstitial alvelolar PNA.  Patient was placed on NC oxygen.  Patient was admitted to hospital services.  On 12/28/2021, rapid response called, family requested hospice services.  Covid-19 PCR came back positive on 12/29/2021.  Patient expired on 12/30/2021.
When I poked the patient with the needle, he abruptly jerked away. The vaccine was not administered. It ran down his arm. His dad observed the event and verified the vaccine was not administered.
None at the time of injection... tachycardia was detected on 12/09/2021
Swollen lymph nodes under right arm/ Swelling of groin lymph nodes; experienced swelling of arm; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Swollen lymph nodes under right arm/ Swelling of groin lymph nodes) and PERIPHERAL SWELLING (experienced swelling of arm) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     Concomitant products included TRAMADOL and PARACETAMOL (TYLENOL).    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced PERIPHERAL SWELLING (experienced swelling of arm). On 29-Jan-2021, the patient experienced LYMPHADENOPATHY (Swollen lymph nodes under right arm/ Swelling of groin lymph nodes). The patient was treated with CELECOXIB (COXIB [CELECOXIB]) for Phlebitis, at an unspecified dose and frequency and HYDROCORTISONE ACETATE (CORTIZONE [HYDROCORTISONE ACETATE]) at an unspecified dose and frequency. On 31-Jan-2021, LYMPHADENOPATHY (Swollen lymph nodes under right arm/ Swelling of groin lymph nodes) had resolved. In July 2021, PERIPHERAL SWELLING (experienced swelling of arm) outcome was unknown. Not provided.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.  Treatment mediations includes alcohol cortisone cream salve   This case was linked to MOD-2021-029552 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Jul-2021: Treatment medications updated.
Systemic: Confusion-Medium, Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Medium, Additional Details: fell out of bed -- called ED but ems did not take to hospital she said bc vitals were normal
Mania, panic attacks, severe insomnia, rash, lesions, confusion, delirium, body aches, headache, anxiety.
exposed 14MAY97 to brother w/varicella 1st pox noted 29MAY97;today is day 4 of illness 2 pink papules, 1on back, 5 on abd, 1 rt axillae, 1 lt arm, 1 penis, 2 on buttocks;lesions were vesicular then receded t100;
1 week after administration, pt. presented with pallor, lethargy, neck mass, anemia, thrombocytopenia. Pt. admitted to hospital. Dx leukemia.
The patient recieved a pediatric dose of Hepatitis A instead of receiving the correctly ordered state supplied Tetanus vaccine. There was no harm/adverse reaction at the time or following administration of the vaccine.
At 1 am the morning after my vaccine, I woke up shaking and shivering. Body aches very bad. Temp pf 101. Took motrin and got very nauseous. I was able to go back to sleep. Woke up a few hours later covered in sweat. Fever broke.  All of 2-4-2021 I was very tired with body aches.  2-5-2021. I noticed a patchy red rash on my right arm, a few inches below injection site.  2--6-2021. I continue to have a red splotchy arm at injection site.
Client presented for a Pfizer vaccine and was given a Janssen dose.  Med error, vials similar in size. Client was informed.
PREGNANT; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (PREGNANT) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE], VALACICLOVIR HYDROCHLORIDE (VALTREX) and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 08-Jul-2020 and the estimated date of delivery was 14-Apr-2021. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (PREGNANT). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirty-eighth week of the pregnancy.  At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (PREGNANT) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Allergy shots are listed in concomitant drugs.  No treatment medication were reported.
Swelling in arm on day 1 and 2,  headache for two days,  Lymph node swollen Day 3.
This is a spontaneous report from a contactable physician via Pfizer sales representative. A male patient of unspecified age and ethnicity received the first dose of TRUMENBA via an unspecified route of administration, on unknown date, at a single dose. Relevant medical history and concomitant medications were not reported. The patient experienced severe pain and limitation of arm movement on unknown date with outcome of unknown. The physician wanted to know if there were patients who have pain from one dose prone to having pain from the whole series.
Patient reported being flushed; slightly short of breath; and a severe headache. EMS was called at the patient's request and she was examined by them. She later saw her primary care provider that day and they reported she is fine.
rash on abdomen and a little onto back; This case was reported by a consumer via call center representative and described the occurrence of rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 3 days after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was recovered/resolved.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional information received were as follows: The age at vaccination was not reported. The caller reported that 3 days after getting Shingrix, she developed a rash on her abdomen and a little onto her back.  The rash was not itchy or raised.  The event resolved in about 2 to 3 days.  The caller would provide only her initials.
Information has been received from a physician's assistant concerning a patient who was vaccinated PO with a dose of Rotateq. Subsequently the patient experienced intussusception and was hospitalized. Surgery was required. The patient recovered. No additional information was available. Intussusception was considered to be immediately life-threatening by the reporter. Additional information has been requested. 10/12/07-records received for DOS 5/23-5/29/07- DC DX: Intussusception. Open reduction with decompressive enterotomy and appendectomy. Presented with 2 day history of vomiting and alternating lethargy and crying. Post operative ileus
Spot where the shot was is swollen; Very tired/Tired as hell/tiredness; My arm is in pain/Arm hurts; Feeling all kinds of discomfort; Very sleepy; Feeling pain; Chills; My arm is now magnetic; Arm hurts and is swollen; This is a spontaneous report received from a contactable consumer or other non-health care professional (patient). A patient of unspecified age and gender received unknown dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: Unknown), via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Consumer stated, I had the shot done Saturday, On unknown date and I am just feeling all kinds of discomfort and very sleepy, but the real thing I called you about was now that spot where I had the shot was magnetic. I could actually put a coin there, any type of coin and it will stay there, it will not move. What was put in my arm. Consumer stated, No, listen to what I said, I said I could move my arm, but my arm is in pain, and the spot where the shot was is swollen, also I am very tired. But the point that I was called to make, now if I put a coin on the spot where I had the shot, it stays there, my arm is now magnetic. Consumer stated, Right now I had the shot Saturday, feeling pain, experienced tiredness and chills. I could put a coin up there and it will not move unless I take it off. What you put in my arm that was now turned me into some bionic creature. Because now I am magnetic. Patient had the Pfizer shot on Saturday. I had the card right here in front of me. Consumer stated, I do not feel that, I know it was. There was a coin on my arm right now, the coin has been on my arm for an hour, it does not move unless I move it, so now I am magnetic. So, on top of this my arm hurts and is swollen and then I can not had this pain because I am tired as hell, now my arm was magnetic. I was just fine before I get the shot, I never had COVID, I never had it. I want to know what this magnetic stuff was in my arm. The outcome of the events was reported as unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
JOINT PAIN IN GREAT TOE AND 2 TOES NEXT OF RIGHT FOOT; NUMBNESS IN GREAT TOE AND 2 TOES NEXT OF RIGHT FOOT; TINGLING IN GREAT TOE AND 2 TOES NEXT OF RIGHT FOOT; This spontaneous report received from a patient concerned a 62 year old male. The patient's weight was 160 pounds, and height was 69 inches. The patient's concurrent conditions included non-alcohol user, and non-smoker, and other pre-existing medical conditions included patient had no known allergies and no drug abuse or illicit drug usage. patient was not taking any daily medications and did not have any medical conditions. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced numbness in great toe and 2 toes next of right foot. On APR-2021, the subject experienced tingling in great toe and 2 toes next of right foot. On an unspecified date, the subject experienced joint pain in great toe and 2 toes next of right foot. Laboratory data (dates unspecified) included: Pain scale (NR: not provided) 5-6/10 pain scale level. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from numbness in great toe and 2 toes next of right foot, tingling in great toe and 2 toes next of right foot, and joint pain in great toe and 2 toes next of right foot. This report was non-serious.
Information has been received from a physician concerning a 13 year old female patient who on unspecified date was vaccinated with a dose of GARDASIL (lot number not provided). The physician reported that the patient developed lymphadenopathy on an unspecified date. At the time of the report the patient's outcome was unknown. It was unspecified if the patient sought medical attention. Follow up information has been received from the physician's office. It was confirmed that there was a patient with lymphadenopathy. Attempts are being made to verify the existence of an identifiable patient. This is one of the several report received from the same source. The person in the office contacted during telephone follow up could not supply the following information: patient's name, date of birth, dates of vaccination, dose number (if applicable), lot number, date of event, recovery status, hospital name (if applicable), healthcare provider name and contact information. Additional information has been requested.
Adverse Event: Dizziness x2 days, Dehydration, elevated fasting blood sugar Treatment: Administered 20 mL of Promethazine HCl 6.25 MG/5ML, Administered IV fluids (1000 mL of Sodium Chloride 0.9 %) Outcomes: Patient stable upon discharge, ER precautions with worsening sxs
Information has been received from a lawyer regarding a case in litigation a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided. On an unknown date in 2008, the patient was vaccinated with ZOSTAVAX as recommended for routine adult health maintenance and for the prevention of shingles (dose, route of administration, anatomical location, lot#, expiration date were unknown). The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster or shingles (onset date was not provided). On an unknown date in 2016, the patient was treated by the physician for a severe vesicular outbreak and decreased immune symptoms which was then diagnosed as severe herpes zoster, or shingles. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. The reporter determined the events to be related to the ZOSTAVAX.
Patient felt tightness of chest, 102-103 degree fever, lethargic, pain and swelling in shoulder/upper arm, warm to touch. Went to local Emergency Room, increased WBC's. Numb face, sore neck.
Patient reports that a few hours after receiving the vaccine, she broke out in a pruritic rash on her face and forearms which is still persisting 7 days post vaccine administration. Symptoms have not improved with Claritin. Pt denies lip/tongue/throat swelling, dyspnea, chest pain, nausea, vomiting, diarrhea or any mental status changes.